Advanced in Transient Ischemic Attack (TIA)

Georg Royl

Ratzeburger Allee 160, 
Luebeck, SH, DE 
Advanced in Transient Ischemic Attack (TIA)
Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Georg Royl practices in Luebeck, Germany. Mr. Royl is rated as an Advanced expert by MediFind in the treatment of Transient Ischemic Attack (TIA). His top areas of expertise are Stroke, Transient Ischemic Attack (TIA), Cerebral Amyloid Angiopathy, Teratoma of the Mediastinum, and Thrombectomy.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Transient Ischemic Attack (TIA).

Gender
Male

Locations

Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Other Locations
Ratzeburger Allee 160, Luebeck, SH 23562, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Diagnostic test
EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation (ENRICH-AF)
EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation (ENRICH-AF)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Other
Study Drug: Edoxaban
Study Phase: Phase 4
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF)
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Apixaban, Dabigatran, Edoxaban, Rivaroxaban
Study Phase: Phase 3
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Phase: Not Applicable
View 3 Less Clinical Trials

45 Total Publications

Ischemic Lesion Net Water Uptake for the Prediction of Very Poor Functional Outcomes at 90 Days.
Ischemic Lesion Net Water Uptake for the Prediction of Very Poor Functional Outcomes at 90 Days.
Journal: Neurology
Published: September 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Royl's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile